ISIN | LU2488092649 |
---|---|
Valor Number | 119403766 |
Bloomberg Global ID | |
Fund Name | Kieger Sustainable Healthcare Fund Class B EUR Accumulating |
Fund Provider |
Kieger AG
Kieger AG Limmatstrasse 264, CH-8005 Zürich Phone: +41 44 444 18 44 Web: https://kieger.com/ E-Mail: info@kieger.com |
Fund Provider | Kieger AG |
Representative in Switzerland |
ACOLIN Fund Services AG Zürich Phone: +41 44 396 96 96 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related issuers worldwide (including Emerging Markets). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 114.03 EUR | 21.11.2024 |
---|---|---|
Previous Price * | 113.10 EUR | 20.11.2024 |
52 Week High * | 119.70 EUR | 30.08.2024 |
52 Week Low * | 97.51 EUR | 28.11.2023 |
NAV * | 114.03 EUR | 21.11.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 296,893,053 | |
Unit/Share Assets *** | 122,036 | |
Trading Information SIX |
YTD Performance | +10.26% |
29.12.2023 - 21.11.2024
29.12.2023 21.11.2024 |
---|---|---|
YTD Performance (in CHF) | +10.29% |
29.12.2023 - 21.11.2024
29.12.2023 21.11.2024 |
1 month | -2.71% |
21.10.2024 - 21.11.2024
21.10.2024 21.11.2024 |
3 months | -2.41% |
21.08.2024 - 21.11.2024
21.08.2024 21.11.2024 |
6 months | -0.37% |
22.05.2024 - 21.11.2024
22.05.2024 21.11.2024 |
1 year | +16.14% |
21.11.2023 - 21.11.2024
21.11.2023 21.11.2024 |
2 years | +14.03% |
06.07.2023 - 21.11.2024
06.07.2023 21.11.2024 |
3 years | - | - |
5 years | - | - |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 5.55% | |
---|---|---|
Merck & Co Inc | 5.32% | |
Novo Nordisk AS Class B | 4.83% | |
UnitedHealth Group Inc | 4.68% | |
Thermo Fisher Scientific Inc | 4.52% | |
Abbott Laboratories | 4.32% | |
AstraZeneca PLC | 4.17% | |
GSK PLC | 4.16% | |
Stryker Corp | 4.02% | |
Boston Scientific Corp | 3.85% | |
Last data update | 30.04.2024 |
TER *** | 0.99% |
---|---|
TER date *** | 30.09.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.85% |
Ongoing Charges *** | |
SRRI ***
|
|
SRRI date *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** |
Sustainable Investment |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |